Treatment of Gout and Hyperuricemia
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 9,216,179 | Treatment of Gout and Hyperuricemia In force · High confidence | Ardea Biosciences, Inc. | In force | High confidence | ||
| Application 14/939,963 | Treatment of Gout and Hyperuricemia Abandoned Abandoned Jul 23, 2017 | Ardea Biosciences, Inc. | Abandoned | Abandoned Jul 23, 2017 | ||
| Application 15/624,818 | Treatment of Gout and Hyperuricemia Abandoned Abandoned Jan 29, 2018 | Ardea Biosciences, Inc. | Abandoned | Abandoned Jan 29, 2018 | ||
| Application 15/878,679 | Treatment of Gout and Hyperuricemia Abandoned Abandoned Sep 21, 2018 | Ardea Biosciences, Inc. | Abandoned | Abandoned Sep 21, 2018 | ||
| Application 16/135,153 | Treatment of Gout and Hyperuricemia Abandoned Abandoned Dec 12, 2018 | Ardea Biosciences, Inc. | Abandoned | Abandoned Dec 12, 2018 |
5 of 5 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
1 of these is in force and held by Ardea Biosciences, Inc..
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.